secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTELO BIOSCIENCES, INC. (ARTL)
CIK:        0001621221
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001640334-22-000444
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artelo Bio CAReS trial on track; board approves 2022 goals, cuts quorum to 35%
------------------------------------------------------------------------------

- CEO Gorgas eligible for 2022 bonus based on goals: clinical (40%), pre-clinical (35%), financial (25%).
- Bylaws amended to reduce shareholder quorum requirement to 35%.
- CAReS Phase 1 enrollment for ART27.13 expected to complete by end of Q1 2022.
- Phase 1 results to inform dose selection within ~6 weeks of last patient; optional fourth cohort possible.
- Company currently sees no significant COVID-19 impact on trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621221/000164033422000444/0001640334-22-000444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621221/000164033422000444/artl_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-22-000444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer